BEERSE, Bélgica, December 4 /PRNewswire/ --
-- Los datos de Ortho Biotech Oncology Research & Development se presentarán en el 51 congreso anual de la American Society of Hematology (ASH)
-- Nota: este comunicado corresponde a los abstracts ASH 109, 131, 1836, 2312, 3859, 3875 y 4045
Ortho Biotech Oncology Research & Development, una división de Janssen Pharmaceutica N.V., ha anunciado hoy que los datos relativos a varios de sus compuestos oncológicos se presentarán en el 51 congreso anual de la American Society of Hematology (ASH) en New Orleans, Louisiana, del 5 al 8 de diciembre de 2009.
"Como organización, estamos muy comprometidos con cumplir las necesidades de los pacientes con desórdenes hematológicos, y avanzar la ciencia en este área", dijo Peter Ho, responsable de Development for Oncology, Ortho Biotech Oncology Research & Development. "En este magnífico momento de la investigación clínica, estamos encantados de que estos datos se presenten en la ASH".
Los siguientes estudios clínicos, seleccionados para la presentación oral - poster, fueron patrocinados por: Ortho Biotech Oncology Research & Development o sus miembros, como: Johnson & Johnson Pharmaceutical Research & Development, LLC; Centocor Ortho Biotech Inc.; Centocor R&D; o Janssen-Cilag GmbH. (Observe que estos estudios se agrupan por compuesto y se detallan en orden cronológico dentro de cada sección.):
[TAB]
VELCADE(R) (bortezomib)
- VELCADE, Intravenous Cyclophosphamide and Dexamethasone (VCD) Induction
for Previously Untreated Multiple Myeloma (German DSMM XIa Trial)
(Abstract 131)
Sesión oral: Myeloma - Therapy, excluding Transplantation: Combination
Therapy for Newly Diagnosed Multiple Myeloma
Domingo, 6 de diciembre de 2009, 5:30 PM CST, Hall F (Ernest N. Morial
Convention Center)
[FTAB]
Autores: H. Einsele, P. Liebisch, C. Langer, M. Kropff, H. Wandt, W. Jung, N. Kroger, M. Engelhardt, H. Ostermann, LO. Mugge, HH. Wolf, C. Hart, B. Metzner, M. Kaufmann, M. Gramatzki, B. Hertenstein, T. Fischer, K. Weisel, G. Dolken, W. Brugger, H. Gollasch, G. Maschmeyer, M. Pfreundschuh, N. Schmitz, O. Sezer, E. Heidemann, E. Jager, C. Kahl, A. Kiani, T. Dechow, W. Rosler, J. P. Simon, H. Durk, K. H. Pfluger, M. Bentz, G. Hess, HG. Mergenthaler, C. Straka, D. Hempel, HJ. Salwender, G. Fingerle-Rowson, S. Knop; University Hospital, Wurzburg, Alemania; University Hospital, Ulm, Alemania; University Hospital, Munster, Alemania; Klinikum Nord, Nuremberg, Alemania; Hematology and Oncology, University Hospital, Gottingen, Alemania; University Hospital Hamburg-Eppendorf, Hamburgo, Alemania; University Hospital, Freiburg, Alemania; University Hospital Grosshadern, Munich, Alemania; University Hospital, Jena, Alemania; University Hospital, Halle, Alemania; University Hospital, Regensburg, Alemania; Klinikum Oldenburg, Oldenburg, Alemania; Robert Bosch-Hospital, Stuttgart, Alemania; University Hospital, Kiel, Germany; Klinikum Bremen-Mitte, Bremen, Alemania; University Hospital, Magdeburg, Alemania; University Hospital, Tubingen, Alemania; University Hospital, Greifswald, Alemania; Schwarzwald-Baar Clinic, Villingen, Alemania; Helios Klinikum, Berlin-Buch, Alemania; Dept. of Hematology/ Oncology, Ernst-von-Bergmann Clinic, Potsdam, Alemania; University of Saarland, Homburg, Germany; Asclepios Clinic St. Georg, Hamburgo, Alemania; University Hospital Charite, Berlin, Alemania; Diakonie-Hospital, Stuttgart, Alemania; Hospital Nordwest GmbH, Frankfurt; University of Rostock, Rostock, Alemania; University Hospital, Dresden, Alemania; Klinikum Rechts-der-Isar, Munich, Alemania; University Hospital, Erlangen, Alemania; University Hospital Schleswig-Holstein, Lubeck, Alemania; Marien Hospital, Hamm, Alemania; Diakonie Hospital, Bremen, Alemania; Klinikum Karlsruhe, Alemania; Johannes Gutenberg-University, Mainz, Alemania; Klinikum Stuttgart, Stuttgart, Alemania; Clinic Dr. Argirov, Berg, Alemania; Center of Oncology, Rehling, Alemania; Asclepios Clinic Altona, Hamburgo, Alemania; Janssen-Cilag GmbH, Neuss, Alemania
[TAB]
- Bortezomib, Thalidomide, and Dexamethasone (VTD) Versus VTD Plus
Cyclophosphamide as Induction Therapy in Previously Untreated Multiple
Myeloma Patients Eligible for HDT-ASCT: A Randomized Phase 2 Trial
(Abstract 2312)
Sesión poster: Clinical Results - Autologous Transplantation Poster II
Domingo, 6 de diciembre de 2009, 6:00 -8:00 PM CST, Hall E (Ernest N.
Morial Convention Center), Poster Board II-289
[FTAB]
Autores: H. Ludwig, L. Viterbo, R. Greil, T. Masszi, I. Spicka, O. Shpilberg, R. Hajek, A. Dmoszynska, A. Cakana, C. Enny, H. Feng, H. van de Velde, JL. Harousseau; 1st Department of Internal Medicine, Center for Oncology and Haematology, Wilhelminenspital, Viena, Austria; Instituto Portugues de Oncologia do Porto Francisco Gentil, Entidade Publica Empresarial (IPOPFG, EPE), Porto, Portugal; Universitatsklinik fur Innere Medizin III, Salzburg, Austria; St Istvan and St Laszlo Hospital, Budapest, Hungary; First Faculty of Medicine,1st Medical Department - Clinical Department of Haematology, Charles University, Praga, República Checa; Rabin Medical Center, Petah-Tiqva, Israel; Clinic of Internal Medicine - Hematology and Oncology, Faculty Hospital Brno, Brno, República Checa; Haematology and BMT Department, Medical University of Lublin, Lublin, Polonia; Johnson & Johnson Pharmaceutical Research & Development, High Wycombe, Reino Unido; Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, NJ; Johnson & Johnson Pharmaceuticals Research & Development, Beerse, Bélgica; Centre Rene Gauducheau, Nantes/St Herblain, Francia
[TAB]
- Bortezomib Plus Melphalan-Prednisone Continues to Demonstrate a
Survival Benefit Vs Melphalan-Prednisone in the Phase III VISTA Trial in
Previously Untreated Multiple Myeloma After 3 Years' Follow-up and
Extensive Subsequent Therapy Use (Abstract 3859)
Sesión poster: Myeloma - Therapy, excluding Transplantation Poster III
Lunes, 7 de diciembre de 2009, 6:00 -8:00 PM CST, Hall E (Ernest N. Morial
Convention Center), Poster Board III-795
[FTAB]
Autores: MV. Mateos, P. G. Richardson, R. Schlag, N. K. Khuageva, M. A. Dimopoulos, O. Shpilberg, M. Kropff, I. Spicka, M. T. Petrucci, A. Palumbo, O. S. Samoilova, A. Dmoszynska, K. M. Abdulkadyrov, R. Schots, B. Jiang, DL. Esseltine, K. Liu, A. Z. Cakana, H. van de Velde, J. F. San Miguel; Hospital Universitario de Salamanca, Salamanca, España; Dana-Farber Cancer Institute, Boston, MA; Praxis for Hematology and Oncology, Wurzburg, Alemania; Hematology Department, SP Botkin Moscow City Clinical Hospital, Moscú, Rusia; Department of Clinical Therapeutics, Alexandra Hospital, University of Athens School of Medicine, Atenas, 11528, Grecia; Rabin Medical Center, Petah-Tiqva, Israel; University of Munster, Munster, Alemania; First Faculty of Medicine,1st Medical Department - Clinical Department of Haematology, Charles University, Prague, República Checa; Division of Hematology, University La Sapienza, Roma, Italia; Division of Hematology, University of Torino, Torino, Italia; Nizhnii Novgorod region Clinical Hospital, Rusia; Hematooncology and Bone Marrow Transplantation, Medical University of Lublin, Lublin, Polonia; St Petersburg Clinical Research Institute of Hematology & Transfusiology, Rusia; Myeloma Study Group, Belgian Hematological Society, Bruselas, Bélgica; People's Hospital, Peking University, China; Millennium Pharmaceuticals, Inc., Cambridge, MA; Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, NJ; Johnson & Johnson Pharmaceutical Research & Development, High Wycombe, Reino Unido; Johnson & Johnson, Bélgica
(CONTINUA)
